Vijay Bahl, MD
Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1912084625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $835,280 of the $997,685 with a category attached, or 83.7%. 60 manufacturers reported payments, led by Lilly USA, LLC at 40.9% of the total. Reporting peaked in 2019 at $267,279 and has fallen 52.2% since, to $127,868 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,910 payments — averaging $342.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$408K
- Novo Nordisk$153K
- Bayer$100K
- Johnson & Johnson$86K
- Sanofi-aventis U.S. LLC$69K
- AstraZeneca$62K
- plus $120K from 54 others
What the payments were for
- Consulting fees$15,4412%
- Speaking & faculty fees$835,28084%
- Travel & lodging$96,73810%
- Food & beverage$49,9025%
- Education$3240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$997,685 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 671 | $838,974 |
| JardianceEmpagliflozin | 383 | $389,630 |
| MounjaroTirzepatide | 285 | $353,280 |
| FarxigaDapagliflozin Propanediol | 292 | $255,860 |
| TrulicityDulaglutide | 202 | $254,411 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $232,841 |
| Tresiba Flextouch U-200Insulin Degludec | 142 | $182,247 |
| TradjentaLinagliptin | 161 | $149,869 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 82 | $105,345 |
| KerendiaFinerenone | 102 | $103,202 |
| Levothyroxine Sodium | 456 | $70,564 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 67 | $69,983 |
| Humalog Kwikpen U-100Insulin Lispro | 174 | $56,853 |
| ProliaDenosumab | 31 | $54,034 |
| SynthroidLevothyroxine Sodium | 576 | $53,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $152,660 | $909,315705 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto Xr, Jentadueto | $29,642 | $656,725671 claims |
| Lilly USA, LLCMounjaro, Trulicity | $408,367 | $607,692487 claims |
| AstraZenecaFarxiga | $61,749 | $255,860292 claims |
| MerckJanumet Xr, Januvia, Janumet | $8,921 | $133,605145 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $69,374 | $105,34582 claims |
| BayerKerendia | $99,923 | $103,202102 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $1,882 | $70,564456 claims |
| AmgenProlia | $16,011 | $54,03431 claims |
| AbbVieSynthroid | $7,043 | $53,781576 claims |
| Johnson & JohnsonInvokana | $86,090 | $32,51727 claims |
| PfizerEliquis | $138 | $17,65422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Pittsburgh
- Swarna VarmaPittsburgh$520K
- Sachin BahlPittsburgh$162K
- Peter GrondziowskiPittsburgh$143K
- Patricia BononiPittsburgh$91K
- Murray GordonPittsburgh$60K
- Frederico ToledoPittsburgh$50K
- Hugo LinPittsburgh$21K
- Pouneh FazeliPittsburgh$20K
- Serge JabbourPhiladelphia$1.2M
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.